Fusion molecules

US10947284B2 · kind B2 · utility

Assignee

• Pieris Pharmaceuticals GmbH · DE

Inventors

• Carsten Corvey · Frankfurt am Main, DE
• Heike Stump · Karben, DE
• Jochen Kruip · Frankfurt am Main, DE
• Christian Lange · Frankfurt am Main, DE
• Ingo Focken · Hofheim, DE
• Dorothea Rat · Frankfurt am Main, DE
• Thomas Stuedemann · Frankfurt am Main, DE
• Hans-Falk Rasser · Frankfurt am Main, DE
• Juergen Schaefer · Frankfurt am Main, DE
• Bernard Calandra · Paris, FR
• Astrid Rey · Paris, FR
• Michael Mourez · Toulouse, FR
• Laurent Fraisse · Toulouse, FR
• Christine Rothe · Freising, DE
• Andrea Allersdorfer · Wolnzach, DE
• Alexander Wiedenmann · Ulm, DE
• Marlon Hinner · Freising, DE
• Bradley M. Lunde · Lebanon, US
• Kristian Jensen · Munich, DE
• Martin Hülsmeyer · Römerberg, DE

Key dates

• Filing date: Apr 24, 2019
• Grant date: Mar 16, 2021
• Expiry date: Apr 24, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/70
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to fusion molecules that have binding specificity for pyoverdine type I, II and III and pyochelin and can be used in various applications, including diagnostic and/or therapeutic applications, for example, to inhibit or reduce growth of P. aeruginosa and/or to prevent or treat P. aeruginosa biofilm infection as well as diseases or disorders associated with P. aeruginosa biofilm infection. The present invention also concerns methods of producing the fusion molecules described herein as well as compositions and kits comprising such fusion molecules. The present invention further relates to nucleic acid molecules encoding the fusion molecules described herein.